PDE 10a Inhibitors for the Treatment of Type II Diabetes
申请人:Janssen Pharmaceutica, NV
公开号:US20140364413A1
公开(公告)日:2014-12-11
Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows:
wherein R
1
, R
2
, L, and Q are defined herein.
Cross-coupling product 2-(2-pyridyl)quinolines were obtained in the reaction of 2-(methylsulfinyl)quinolines and 2-(methylsulfinyl)pyridines with methylmagnesium bromide. Attempts of cross coupling in the reaction of other substrates were unsuccessful.
COMPOUNDS FOR INHIBITING C-MYC/MAX/DNA COMPLEX FORMATION
申请人:NATIONAL CANCER CENTER
公开号:US20180029988A1
公开(公告)日:2018-02-01
Disclosed are novel compounds of specific chemical structures having inhibitory activity on c-Myc/Max/DNA complex formation or pharmaceutically acceptable salts thereof.
Compounds for inhibiting c-myc/max/DNA complex formation
申请人:NATIONAL CANCER CENTER
公开号:US10227306B2
公开(公告)日:2019-03-12
Disclosed are novel compounds of specific chemical structures having inhibitory activity on c-Myc/Max/DNA complex formation or pharmaceutically acceptable salts thereof.
Provided is a method for treating or preventing cancer, containing, as an active ingredient, a compound having a specific chemical structure and an activity of inhibiting the formation of a c-Myc/Max/DNA complex, or a pharmaceutically acceptable salt thereof.